Edition:
United States

Cidara Therapeutics Inc (CDTX.OQ)

CDTX.OQ on NASDAQ Stock Exchange Global Market

4.35USD
17 Aug 2018
Change (% chg)

$0.10 (+2.35%)
Prev Close
$4.25
Open
$4.25
Day's High
$4.35
Day's Low
$4.20
Volume
11,478
Avg. Vol
27,490
52-wk High
$8.80
52-wk Low
$3.65

Chart for

About

Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio... (more)

Overall

Beta: 1.97
Market Cap(Mil.): $117.63
Shares Outstanding(Mil.): 27.68
Dividend: --
Yield (%): --

Financials

  CDTX.OQ Industry Sector
P/E (TTM): -- 95.67 30.17
EPS (TTM): -3.35 -- --
ROI: -72.26 3.33 12.67
ROE: -96.33 2.31 14.86

BRIEF-Cidara Announces Stock And Warrants Offering Worth $120 Mln

* CIDARA THERAPEUTICS ANNOUNCES OFFERING OF COMMON STOCK AND WARRANTS

May 21 2018

BRIEF-Cidara Therapeutics Files For Stock Shelf Of Up To $10 Mln

* CIDARA THERAPEUTICS INC FILES FOR STOCK SHELF OF UP TO $10 MILLION – SEC FILING Source text (https://bit.ly/2kebUqL) Further company coverage:

May 21 2018

BRIEF-Cidara Reports Q1 Loss Per Share $0.80

* CIDARA PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 10 2018

BRIEF-Cidara Says Additional Data Confirm Positive Results In Antifungal Rezafungin

* CIDARA THERAPEUTICS PROVIDES CLINICAL DATA UPDATES FOR ITS LEAD ANTIFUNGAL REZAFUNGIN

Mar 21 2018

BRIEF-Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin

* CIDARA THERAPEUTICS REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 STRIVE TRIAL OF LEAD ANTIFUNGAL REZAFUNGIN

Mar 19 2018

BRIEF-Cidara Posts Q4 Loss Per Share $0.69​

* CIDARA PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 27 2018

Earnings vs. Estimates